Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients

Mina sobhi said fam2 个研究点分布在 1 个国家目标入组 50 人2022年6月1日

适应症COVID-19 Vaccine

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: COVID-19 Vaccine
发起方: Mina sobhi said fam
入组人数: 50
试验地点: 2
主要终点: Myocardial infarction
最后更新: 4年前

概览研究者入排标准结局指标研究点相似试验

概览

简要总结

Efficacy and safety of covid-19 vaccine in Cardiac patients

详细描述

investigate the efficacy and safety of covid-19 vaccine in cardiac patients and its possible assocciated morbidity

注册库

clinicaltrials.gov

开始日期

2022年6月1日

结束日期

2023年9月1日

最后更新

4年前

研究类型

Observational

性别

All

研究者

发起方

Mina sobhi said fam

责任方

Sponsor Investigator

主要研究者

Mina sobhi said fam

resident doctor

Assiut University

入排标准

入选标准

•Subjects diagnosed as STEMI undergo PPCI as (Fourth universal definition of myocardial infarction (2018) Kristian Thygesen) 10
•with age range from 18 to 80 years after 1 month of STEMI .

排除标准

•Patients with previous covid infection confirmed by swap or CT chest or ICU addmision.
•Patients with previous covid infection confirmed by qualitative antibdy test .
•Patients with history of anaphylaxis to any component of the vaccine should not take it .
•patients with febrile illness or acute , ongoing infection .
•immunosuppressive diseases .

结局指标

主要结局

Myocardial infarction

时间窗: one year

Myocardial infarction

stent thrombosis

时间窗: one year

stent thrombosis

all cause mortality

时间窗: one year

all cause mortality

次要结局

heart failure hospitalization(one year)
anaphylaxis required hospitalization(one year)
Cardiovascular death. Cardiovascular death. Cardiovascular death.Cardiovascular death. cardiovascular death(one year)
infection by covid-19(one year)